UK markets closed
  • NIKKEI 225

    -584.99 (-1.97%)

    +29.58 (+0.10%)

    +0.17 (+0.27%)

    +0.40 (+0.02%)
  • DOW

    -256.33 (-0.75%)

    -298.84 (-0.73%)
  • CMC Crypto 200

    +62.00 (+5.02%)
  • ^IXIC

    -128.50 (-0.92%)
  • ^FTAS

    -76.60 (-1.92%)

2021 World Inflammatory Pain Pipeline Insight

Research and Markets
·3-min read

Dublin, March 10, 2021 (GLOBE NEWSWIRE) -- The "Inflammatory Pain - Pipeline Insight, 2021" drug pipelines has been added to's offering.

This "Inflammatory Pain - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Inflammatory Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The report provides comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Inflammatory Pain pipeline landscape is provided which includes the disease overview and Inflammatory Pain treatment guidelines. The assessment part of the report embraces, in depth Inflammatory Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals and product development activities comprising the technology, Inflammatory Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Inflammatory Pain R&D. The therapies under development are focused on novel approaches to treat/improve Inflammatory Pain.

The report covers around 3+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Inflammatory Pain Report Insights

  • Inflammatory Pain Pipeline Analysis

  • Therapeutic Assessment

  • Unmet Needs

  • Impact of Drugs

Inflammatory Pain Report Assessment

  • Pipeline Product Profiles

  • Therapeutic Assessment

  • Pipeline Assessment

  • Inactive drugs assessment

  • Unmet Needs

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Inflammatory Pain drugs?

  • How many Inflammatory Pain drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Inflammatory Pain?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Inflammatory Pain therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Inflammatory Pain and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Topics Covered:


Executive Summary

Inflammatory Pain: Overview

  • Causes

  • Mechanism of Action

  • Signs and Symptoms

  • Diagnosis

  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type

  • Assessment by Stage and Product Type

  • Assessment by Route of Administration

  • Assessment by Stage and Route of Administration

  • Assessment by Molecule Type

  • Assessment by Stage and Molecule Type

Inflammatory Pain - Analytical Perspective

In-depth Commercial Assessment

  • Inflammatory Pain companies' collaborations, Licensing, Acquisition - Deal Value Trends

Inflammatory Pain Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis

  • Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

  • Comparative Analysis

CNTX 6970: Centrexion Therapeutics

  • Product Description

  • Research and Development

  • Product Development Activities

Early Stage Products (Phase I)

  • Comparative Analysis

AAV-AQP1: Kadmon Gene Therapy

  • Product Description

  • Research and Development

  • Product Development Activities

Inactive Products

  • Comparative Analysis

Inflammatory Pain Key Companies

Inflammatory Pain Key Products

Inflammatory Pain - Unmet Needs

Inflammatory Pain - Market Drivers and Barriers

Inflammatory Pain - Future Perspectives and Conclusion

Inflammatory Pain Analyst Views

Inflammatory Pain Key Companies

For more information about this drug pipelines report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900